Pinnacle Medicines is developing a generation of oral peptide medicines designed to deliver biologic-level efficacy with oral dosing. The company combines physics-based molecular simulations, artificial intelligence–enabled design, and advanced peptide chemistry in a proprietary discovery platform. Pinnacle is advancing a pipeline of potential first- and best-in-class oral peptide programs targeting validated pathways in immunology and cardiometabolic diseases. The recent $89 million Series B will support progressing lead programs toward clinical proof of concept and expanding R&D capabilities. Pinnacle has raised $134 million to date following incubation by OrbiMed and other healthcare specialist investors. The company operates out of Shanghai and Doylestown, Pennsylvania.

Total raised

$89M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2026